Transmembrane transport · target hub

SLC16A1

SLC16A1 (SLC16A1)

SLC16A1 is a SLC peptide / MCT monocarboxylate transport on the transmembrane transport axis. Validate function and tissue distribution with UniProt and primary literature. It is indexed under "SLC16 monocarboxylate transporters (MCT)" on our pathway page for antibodies, inhibitors, and assay guidance.

Research notes

  • Combine with other genes in the same hub block via genetics or pharmacology to test non-redundant roles of SLC16A1.
  • Pair transporter/channel with 13C tracing, Seahorse OCR/ECAR, or metabolomics; nutrient withdrawal/refeed controls.
  • Verify antibody clone, compartment, and stimulation; include KD/KO or inhibitor controls.

On the pathway hub (sections)

Genetic lesions & expression context (quick reference)

Type / exampleDomain / context (brief)
Expression contextTissue/cell-type–dependent expression
Rare variantsSporadic variants—require functional validation
Pathway couplingCo-occurs with neighboring nodes on the hub

Naming and prevalence vary by cohort and assay—annotate clinically with COSMIC, ClinVar, OncoKB, and datasheets; research context only.

Assay readouts for SLC16A1

  • Peptide/MCT: SLC16A1 dipeptide/lactate/ketone transport readouts.
  • pH-gradient assays; MCT inhibitors (e.g., AZD3965) as relevant.
  • Caco-2 bidirectional permeability (Papp) and efflux ratio.
  • Hypoxic lactate secretion vs MCT expression.

SLC16A1 experimental notes

Examples below reflect common literature and public resources (e.g., CCLE, DepMap)—validate genotypes, expression, and passage in your own stocks before committing assays.

[1] Cell lines commonly used for SLC16A1 studies (examples)

  • Tool lines: Caco-2, MDCK, HEK293T, HepG2, HeLa—screen by SLC16A1 expression and pathway context (CCLE/DepMap).
  • Combine with neighbors (SLC16A2, SLC16A3, SLC16A4, SLC16A5) via KD/pharmacology to test non-redundancy.
  • Overexpression/rescue in HEK293T supports mechanism and IP workflows.
  • Isogenic/CRISPR models separate pathway dependency from bypass survival.

[2] Cell samples for SLC16A1 Western blot

  • Whole-cell lysates—optimize RIPA/NP-40 per antibody; phosphatase inhibitors for phospho blots.
  • Stimulation: serum starvation ± insulin/EGF or amino-acid withdrawal/refeed as relevant.
  • Controls: siRNA/shRNA, CRISPR KO, or inhibitors to validate band specificity.
  • Loading: BCA normalization; subcellular fractionation when needed.

[3] Tissue samples for SLC16A1 Western blot

  • Matched tumor/adjacent frozen tissues after pathology review.
  • Mouse GEMM or xenografts—mind species antibody cross-reactivity.
  • Primary cells/PDCs when ethically approved.
  • FFPE needs specialized extraction; frozen tissue preferred for phospho work.

[4] Cell samples for SLC16A1 immunoprecipitation

  • Tagged overexpression: HEK293T FLAG/HA-SLC16A1 for complex capture.
  • Endogenous IP: high-expression lines; often ≥1–5×10⁶ cells per IP.
  • Stimulation: ligand or nutrient treatments enrich interactions—pilot time courses.
  • Controls: isotype IgG, empty vector, KD/KO negatives.

Human tissues and primary cells require ethics/IRB approval; tumors are heterogeneous—record histotype, site, and preservation conditions.

Bypass & related pathways

Models & genetics note

Overexpression vs endogenous SLC16A1 can differ in dosage, splicing, and compartmentation—in organoids/PDX, record passage, matrix, and drug history.

Quick search presets

SLC16A1-related antibodies (keyword-biased)

Adds SLC16A1 keyword bias atop the 跨膜转运 antibody pool—if sparse, use presets above or global search.

FAQ

This content supports research reagents and pathway education—not medical advice. Annotate mutations, drug indications, and protocols with authoritative databases, datasheets, and institutional oversight.

Last reviewed: 2026-05-18

Related on this site

See the metabolism & hormone hub for neighboring targets—cross-check PI3K, MAPK, RTK, and metabolism pages as needed.